GLP1R and type 2 diabetes mellitus: Furthermore, extending the understanding of benefits from GLP-1 RA use in T2D, meta-regression analyses demonstrated that cardiovascular benefits were more pronounced in individuals with higher baseline BMI and older age, with incremental risk reductions in MACE.